Medicines in Development
MOLECULE & POTENTIAL INDICATION DATA AS OF July 29, 2019
Interested in Lilly clinical trials? Learn more at LillyTrialGuide.com
Therapeutic Areas:
Type:
Regulatory Approval Achieved
View Portfolio Minimize Portfolio
Galcanezumab
Cluster Headache
Milestone Achieved
- Pain
- Large Molecule
- New Indication
Galcanezumab
LY2951742, (CGRP monoclonal antibody), is a biologic entity that binds and inhibits the activity of calcitonin gene related peptide (CGRP). LY2951742 is being studied for the prevention of cluster headache.
News (January 1, 2010 - July 29, 2019)
Press Release | November 14, 2018
Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster HeadacheNasal Glucagon
Hypoglycemia
Milestone Achieved
- Diabetes
- Large Molecule
- NME
Nasal Glucagon
Nasal glucagon is a large molecule being studied for the treatment of severe hypoglycemia in people with diabetes treated with insulin.
News (January 1, 2010 - July 29, 2019)
Press Release | October 9, 2015
Lilly Acquires Phase III Intranasal Glucagon From Locemia SolutionsRamucirumab
Hepatocellular Cancer
Milestone Achieved
- Oncology
- Large Molecule
- New Indication
Ramucirumab
(ra" mue sir' ue mab)
LY3009806 (ramucirumab), a biologic entity, is an antiangiogenic therapy. Specifically, it is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D. LY3009806 is currently being studied for the treatment of 2nd line hepatocellular carcinoma.
News (January 1, 2010 - July 29, 2019)
Press Release | January 18, 2019
Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma PatientsPress Release | April 4, 2018
Lilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival EndpointPress Release | June 11, 2014
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma TrialGalcanezumab
Cluster Headache
- Pain
- Large Molecule
- Milestone Achieved
- New Indication
Nasal Glucagon
Hypoglycemia
- Diabetes
- Large Molecule
- Milestone Achieved
- NME
Ramucirumab
Hepatocellular Cancer
- Oncology
- Large Molecule
- Milestone Achieved
- New Indication
Regulatory Review
View Portfolio Minimize Portfolio
Connected Care Pre-Filled Insulin Pen
Diabetes
- Diabetes
- New Formulation
Connected Care Pre-Filled Insulin Pen
This prefilled insulin pen is part of the integrated insulin management system, which includes a Bluetooth-enabled pen attachment and mobile medical application
Dulaglutide REWIND
- Diabetes
- Large Molecule
- New Indication
Dulaglutide REWIND
LY2189265 (dulaglutide), a glucagon-like peptide-1 analog, is a biologic entity being studied for the reduction of cardiovascular events in adults with type 2 diabetes.
Empagliflozin
Type 1 Diabetes
Milestone Achieved
- Diabetes
- Small Molecule
- Commercial Collaboration
- New Indication
Empagliflozin
BI10773 (empagliflozin) is a small molecule that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for type 1 diabetes.
News (January 1, 2010 - July 29, 2019)
Empagliflozin + Linagliptin + Met XR diabetes
- Diabetes
- Commercial Collaboration
- New Formulation
Empagliflozin + Linagliptin + Met XR diabetes
"Empa + Lina + Met XR" is a fixed dose combination of Empagliflozin, a sodium glucose co-transporter-2 inhibitor and Linagliptin, a dipeptidyl peptidase 4 inhibitor with metformin-extended release. It is being studied as a treatment for type 2 diabetes in collaboration with Boehringer Ingelheim.
Ixekizumab
Radiographic Axial Spondyloarthritis
- Immunology
- Large Molecule
- New Indication
Ixekizumab
LY2439821 (ixekizumab) is a large molecule that neutralizes a soluble factor called interleukin-17A (IL-17). LY2439821 is being studied for the treatment of radiographic axial spondyloarthritis.
News (January 1, 2010 - July 29, 2019)
Press Release | October 22, 2018
ACR 2018: Lilly Announces Positive Results for Two Phase 3 Studies of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)Lasmiditan
Migraine
- Pain
- Small Molecule
- NME
Lasmiditan
LY573144 (lasmiditan), a small molecule, is an oral 5-HT1F receptor agonist. LY573144 is being studied for the acute treatment of migraine.
News (January 1, 2010 - July 29, 2019)
Press Release | November 14, 2018
Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Cluster HeadachePress Release | September 9, 2017
IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with MigrainePress Release | August 4, 2017
Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of MigraineUltra-Rapid Lispro
Diabetes
- Diabetes
- Large Molecule
- NME
Ultra-Rapid Lispro
"LY900014" (ultra-rapid lispro) is a novel formulation containing locally-acting excipients to accelerate insulin lispro absorption. LY900014 is a biologic entity being studied for the treatment of type 1 and type 2 diabetes.
News (January 1, 2010 - July 29, 2019)
Connected Care Pre-Filled Insulin Pen
Diabetes
- Diabetes
- New Formulation
Dulaglutide REWIND
- Diabetes
- Large Molecule
- New Indication
Empagliflozin
Type 1 Diabetes
- Diabetes
- Small Molecule
- Milestone Achieved
- New Indication
Empagliflozin + Linagliptin + Met XR diabetes
- Diabetes
- New Formulation
Ixekizumab
Radiographic Axial Spondyloarthritis
- Immunology
- Large Molecule
- New Indication
Lasmiditan
Migraine
- Pain
- Small Molecule
- NME
Ultra-Rapid Lispro
Diabetes
- Diabetes
- Large Molecule
- NME
Phase 3
View Portfolio Minimize Portfolio
Abemaciclib
Adjuvant Breast Cancer
- Oncology
- Small Molecule
- New Indication
Abemaciclib
(a be muh sī klib)
LY2835219 (abemaciclib), a small molecule, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of adjuvant breast cancer.
News (January 1, 2010 - July 29, 2019)
Baricitinib
Alopecia Areata
Milestone Achieved
- Immunology
- Small Molecule
- New Indication
Baricitinib
LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a small molecule that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of alopecia areata.
Baricitinib
Atopic Dermatitis
- Immunology
- Small Molecule
- New Indication
Baricitinib
LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a small molecule that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of atopic dermatitis.
News (January 1, 2010 - July 29, 2019)
Press Release | February 4, 2019
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic DermatitisBaricitinib
Systemic Lupus Erythematosus
- Immunology
- Small Molecule
- New Indication
Baricitinib
LY3009104 (baricitinib, formerly known as JAK1/JAK2 Inhibitor) is a small molecule that inhibits the activity of the Janus (JAK) 1 and 2 enzymes. LY3009104 is being studied for the treatment of systemic lupus erythematosus.
News (January 1, 2010 - July 29, 2019)
Press Release | December 13, 2018
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)Press Release | July 19, 2018
Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)Dulaglutide 3.0 / 4.5 mg
Diabetes
- Diabetes
- Large Molecule
- New Formulation
Dulaglutide 3.0 / 4.5 mg
LY2189265 (dulaglutide), a glucagon-like peptide-1 analog, is a large molecule being studied at investigational doses as a once-weekly treatment for type 2 diabetes.
News (January 1, 2010 - July 29, 2019)
Empagliflozin
Chronic Kidney Disease
- Diabetes
- Small Molecule
- Commercial Collaboration
- New Indication
Empagliflozin
BI10773 (Empagliflozin) is a small molecule that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for chronic kidney disease.
Empagliflozin
Heart Failure
- Diabetes
- Small Molecule
- Commercial Collaboration
- New Indication
Empagliflozin
BI10773 (empagliflozin) is a small molecule that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for chronic heart failure with either preserved or reduced ejection fraction.
News (January 1, 2010 - July 29, 2019)
Press Release | March 17, 2017
First Dedicated Outcome Trials of Eempagliflozin in Chronic Heart Failure InitiatedFlortaucipir F 18
- Neurodegeneration
- Small Molecule
- New Diagnostic
Flortaucipir F 18
(flor tau’ si pir)
Flortaucipir F 18 (formerly known as 18F-AV-1451 or Tau imaging agent) is a small molecule PET imaging agent being studied for the imaging of Tau pathology.
News (January 1, 2010 - July 29, 2019)
Press Release | September 5, 2018
Lilly Announces Positive Phase 3 Results in Study of Flortaucipir PET Imaging AgentPress Release | July 27, 2016
New Studies Suggest Relationship Between Tau Pathology And Progression Of Alzheimer's DiseaseIxekizumab
Non-Radiographic Axial Spondyloarthritis
- Immunology
- Large Molecule
- New Indication
Ixekizumab
LY2439821 (ixekizumab) is a large molecule that neutralizes a soluble factor called interleukin-17A (IL-17). LY2439821 is being studied for the treatment of non-radiographic axial spondyloarthritis.
Mirikizumab
Psoriasis
- Immunology
- Large Molecule
- NME
Mirikizumab
(mir” i kiz’ ue mab)
LY3074828 (formerly known as IL-23 antibody) is a large molecule that blocks the activity of the cytokine interleukin 23. LY3074828 is being studied for the treatment of psoriasis.
Mirikizumab
Ulcerative Colitis
- Immunology
- Large Molecule
- New Indication
Mirikizumab
(mir” i kiz’ ue mab)
LY3074828 (formerly known as IL-23 antibody) is a large molecule that blocks the activity of the cytokine interleukin 23. LY3074828 is being studied for the treatment of ulcerative colitis.
News (January 1, 2010 - July 29, 2019)
Pegilodecakin
Pancreatic Cancer
- Oncology
- Large Molecule
- NME
Pegilodecakin
LY3500518 (pegilodecakin), a large molecule, is a PEGylated IL-10 designed to activate and enhance anti-tumor immune response in cancer patients. LY3500518 is being studied for the treatment of pancreatic cancer.
Ramucirumab
NSCLC
- Oncology
- Large Molecule
- New Indication
Ramucirumab
(ra" mue sir' ue mab)
LY3009806 (ramucirumab), a large molecule, is an antiangiogenic therapy. Specifically, it is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that binds and blocks activation of VEGF Receptor 2 by blocking the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D. LY3009806 is currently being studied for the treatment of first-line, EGFR positive NSCLC.
News (January 1, 2010 - July 29, 2019)
Press Release | October 16, 2017
Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup AnalysisPress Release | June 5, 2016
Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung CancerPress Release | May 18, 2016
ASCO Data Underscore Lilly's Diverse Oncology Pipeline And PortfolioPress Release | May 28, 2015
Lilly To Present CYRAMZA® (Ramucirumab) Data At 2015 ASCO Annual MeetingPress Release | January 13, 2015
Lilly, Merck Enter Collaboration Agreement To Research Immuno-Oncology Combination Regimens In Multiple Types Of CancerSolanezumab
Preclinical Alzheimer’s
- Neurodegeneration
- Large Molecule
- NME
Solanezumab
(soe" la nez' ue mab)
LY2062430 (solanezumab) is a large molecule that binds to soluble monomeric forms of amyloid ß (Ab) after it is produced. LY2062430 is being studied for its potential to slow the progression of Alzheimer's disease.
Tanezumab
Cancer Pain
- Pain
- Large Molecule
- Commercial Collaboration
- New Indication
Tanezumab
(ta nez' oo mab)
Tanezumab, a large molecule, is a monoclonal antibody that inhibits nerve growth factor. Tanezumab is being studied in collaboration with Pfizer for the treatment of cancer pain.
Tanezumab
Chronic Lower Back Pain
- Pain
- Large Molecule
- Commercial Collaboration
- New Indication
Tanezumab
(ta nez' oo mab)
Tanezumab, a large molecule, is a monoclonal antibody that inhibits nerve growth factor. Tanezumab is being studied in collaboration with Pfizer for the treatment of chronic lower back pain.
News (January 1, 2010 - July 29, 2019)
Press Release | June 13, 2017
Pfizer and Lilly Receive FDA Fast Track Designation for TanezumabTanezumab
Osteoarthitic Pain
- Pain
- Large Molecule
- Commercial Collaboration
- NME
Tanezumab
(ta nez' oo mab)
Tanezumab, a large molecule, is a monoclonal antibody that inhibits nerve growth factor. Tanezumab is being studied in collaboration with Pfizer for the treatment of multiple pain indications including osteoarthritis pain.
News (January 1, 2010 - July 29, 2019)
Press Release | January 29, 2019
Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis PainPress Release | October 23, 2018
Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis PatientsPress Release | July 18, 2018
Pfizer and Lilly Announce Positive Top-Line Results from Phase 3 Trial of Tanezumab for the Treatment of Osteoarthritis (OA) PainPress Release | June 13, 2017
Pfizer and Lilly Receive FDA Fast Track Designation for TanezumabPress Release | March 23, 2015
Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For TanezumabTirzepatide
Diabetes
- Diabetes
- Large Molecule
- NME
Tirzepatide
LY3298176 (Dual GIP/GLP-1 Receptor Agonist) is a large molecule that acts as a coagonist for both the gastric inhibitory polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor and is being studied for the treatment of diabetes.
Abemaciclib
Adjuvant Breast Cancer
- Oncology
- Small Molecule
- New Indication
Baricitinib
Alopecia Areata
- Immunology
- Small Molecule
- Milestone Achieved
- New Indication
Baricitinib
Atopic Dermatitis
- Immunology
- Small Molecule
- New Indication
Baricitinib
Systemic Lupus Erythematosus
- Immunology
- Small Molecule
- New Indication
Dulaglutide 3.0 / 4.5 mg
Diabetes
- Diabetes
- Large Molecule
- New Formulation
Empagliflozin
Chronic Kidney Disease
- Diabetes
- Small Molecule
- New Indication
Empagliflozin
Heart Failure
- Diabetes
- Small Molecule
- New Indication
Flortaucipir F 18
- Neurodegeneration
- Small Molecule
- New Diagnostic
Ixekizumab
Non-Radiographic Axial Spondyloarthritis
- Immunology
- Large Molecule
- New Indication
Mirikizumab
Psoriasis
- Immunology
- Large Molecule
- NME
Mirikizumab
Ulcerative Colitis
- Immunology
- Large Molecule
- New Indication
Pegilodecakin
Pancreatic Cancer
- Oncology
- Large Molecule
- NME
Ramucirumab
NSCLC
- Oncology
- Large Molecule
- New Indication
Solanezumab
Preclinical Alzheimer’s
- Neurodegeneration
- Large Molecule
- NME
Tanezumab
Cancer Pain
- Pain
- Large Molecule
- New Indication
Tanezumab
Chronic Lower Back Pain
- Pain
- Large Molecule
- New Indication
Tanezumab
Osteoarthitic Pain
- Pain
- Large Molecule
- NME
Tirzepatide
Diabetes
- Diabetes
- Large Molecule
- NME
Phase 2
View Portfolio Minimize Portfolio
Abemaciclib
HR+/HER2+ Metastatic Breast Cancer
- Oncology
- Small Molecule
- New Indication
Abemaciclib
(a be muh sī klib)
LY2835219 (abemaciclib), a small molecule, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of hormone receptor positive and HER2 positive metastatic breast cancer.
Abemaciclib
Prostate Cancer
- Oncology
- Small Molecule
- New Indication
Abemaciclib
LY2835219 (abemaciclib), a small molecule, is a selective ATP-competitive inhibitor of cyclin dependent kinases (CDK) 4 and 6 that inhibits phosphorylation of the Rb tumor suppressor protein and thereby induces G1 cell cycle arrest. LY2835219 is being studied for the treatment of prostate cancer.
Automated Insulin Delivery System (AID)
Diabetes
- Diabetes
- NME
Automated Insulin Delivery System (AID)
"AID" is an automated insulin delivery system being studied for the treatment of diabetes.
Basal Insulin-Fc
Diabetes
- Diabetes
- Large Molecule
- NME
Basal Insulin-Fc
LY3209590 "Basal insulin-Fc" is a large molecule comprised of an engineered insulin fused to an Fc domain designed to provide a long-acting basal profile. LY3209590 is being studied for the treatment of diabetes.
D1 PAM
Dementia
- Neurodegeneration
- Small Molecule
- NME
D1 PAM
LY3154207 (D1 PAM) is a small molecule that acts as a positive allosteric modulator of the dopamine receptor D1 and is being studied for the treatment of dementia associated with Parkinson's disease.
Donanemab Alzheimer's
Alzheimer's
- Neurodegeneration
- Large Molecule
- NME
Donanemab Alzheimer's
LY3002813 (N3pG-Ab MAb) is a biologic entity that binds to deposited amyloid plaque in brain and is being studied for the treatment of Alzheimer's disease.
IL-33 Antibody Atopic Dermatitis
Autoimmunity
- Immunology
- Large Molecule
- NME
IL-33 Antibody Atopic Dermatitis
Business area: Autoimmunity
LY3375880 "IL-33 Antibody" is a biologic entity that binds to interleukin 33 and is being studied for the treatment of atopic dermatitis.
Mirikizumab
Crohn's Disease
- Immunology
- Large Molecule
- New Indication
Mirikizumab
(mir” i kiz’ ue mab)
LY3074828 (formerly known as IL-23 antibody) is a large molecule that blocks the activity of the cytokine interleukin 23. LY3074828 is being studied for the treatment of Crohn's disease.
Olaratumab
Pancreatic Cancer
- Oncology
- Large Molecule
- New Indication
Olaratumab
LY3012207 (olaratumab), a large molecule, is a human IgG1 monoclonal antibody that binds to the platelet derived growth factor receptor alpha (PDGFRα) and blocks PDGFRα activation. LY3012207 is being studied for the treatment of pancreatic cancer.
Pegilodecakin
NSCLC
- Oncology
- Large Molecule
- New Indication
Pegilodecakin
LY3500518 (pegilodecakin), a large molecule, is a PEGylated IL-10 designed to activate and enhance anti-tumor immune response in cancer patients. LY3500518 is being studied for the treatment of NSCLC.
RET Inhibitor
Cancer
- Oncology
- Small Molecule
- NME
RET Inhibitor
"RET Inhibitor" is a small molecule that inhibits the rearranged during transfection (RET) kinase. It is being studied across multiple tumor types.
TGFß R1 Kinase Inhibitor
Cancer
- Oncology
- Small Molecule
- NME
TGFß R1 Kinase Inhibitor
LY3200882 (TGFß Receptor 1 Kinase Inhibitor) is a small molecule that inhibits the kinase activity of the TGFß receptor 1. LY3200882 is being studied for the treatment of cancer.
Zagotenemab Alzheimer's
Alzheimer's
- Neurodegeneration
- Large Molecule
- NME
Zagotenemab Alzheimer's
Business area: Neuroscience
LY3303560 (Tau Deposit Antibody) is a biologic entity that binds selectively to tau protein deposits in the brain and is being studied for the treatment of Alzheimer's disease.
Abemaciclib
HR+/HER2+ Metastatic Breast Cancer
- Oncology
- Small Molecule
- New Indication
Abemaciclib
Prostate Cancer
- Oncology
- Small Molecule
- New Indication
Automated Insulin Delivery System (AID)
Diabetes
- Diabetes
- NME
Basal Insulin-Fc
Diabetes
- Diabetes
- Large Molecule
- NME
D1 PAM
Dementia
- Neurodegeneration
- Small Molecule
- NME
Donanemab Alzheimer's
Alzheimer's
- Neurodegeneration
- Large Molecule
- NME
IL-33 Antibody Atopic Dermatitis
Autoimmunity
- Immunology
- Large Molecule
- NME
Mirikizumab
Crohn's Disease
- Immunology
- Large Molecule
- New Indication
Olaratumab
Pancreatic Cancer
- Oncology
- Large Molecule
- New Indication
Pegilodecakin
NSCLC
- Oncology
- Large Molecule
- New Indication
RET Inhibitor
Cancer
- Oncology
- Small Molecule
- NME
TGFß R1 Kinase Inhibitor
Cancer
- Oncology
- Small Molecule
- NME
Zagotenemab Alzheimer's
Alzheimer's
- Neurodegeneration
- Large Molecule
- NME
Phase 1
View Portfolio Minimize Portfolio
Aur A Kinase Inhibitor
Cancer
- Oncology
- Small Molecule
- NME
Aur A Kinase Inhibitor
"Aurora A kinase Inhibitor" is a small molecule being studied for the treatment of cancer.
BAFF/IL-17 Bispecific Antibody
Immunology
- Immunology
- Large Molecule
- NME
BAFF/IL-17 Bispecific Antibody
"BAFF/IL-17 Bispecific Antibody" is a large molecule being studied for the treatment of autoimmune diseases.
Basal Insulin Acylated
Diabetes
- Diabetes
- Large Molecule
- NME
Basal Insulin Acylated
"Basal Insulin Acylated" is a large molecule being studied for the treatment of diabetes.
BTK Inhibitor
Cancer
- Oncology
- Small Molecule
- NME
BTK Inhibitor
"BTK inhibitor" is a small molecule being studied for the treatment of cancer.
BTLA Antibody Agonist
Immunology
- Immunology
- Large Molecule
- NME
BTLA Antibody Agonist
"BTLA Agonist Antibody" is a biologic entity being studied for the treatment of autoimmune diseases.
cancer
Oncology
- Oncology
- NME
cancer
A chemical entity being studied for the treatment of cancer.
CD200R Antibody Agonist
Immunology
- Immunology
- Large Molecule
- NME
CD200R Antibody Agonist
"CD200R Antibody Agonist" is a large molecule being studied for the treatment of autoimmune diseases.
CXCR1/2 Ligands Monoclonal Antibody
Immunology
- Immunology
- Large Molecule
- NME
CXCR1/2 Ligands Monoclonal Antibody
"CXCR1/2 Ligands Monoclonal Antibody" is a large molecule being studied for the treatment of autoimmune diseases.
Dual Amylin Calcitonin Receptor Agonist
Diabetes
- Diabetes
- Large Molecule
- NME
Dual Amylin Calcitonin Receptor Agonist
"DACRA-089" is a large molecule being studied for the treatment of diabetes.
ERK Inhibitor
Cancer
- Oncology
- Small Molecule
- NME
ERK Inhibitor
"ERK Inhibitor" is a small molecule being studied for the treatment of cancer.
GDF15 Agonist
Diabetes
- Diabetes
- Large Molecule
- NME
GDF15 Agonist
"GDF15 Agonist" is a large molecule being studied for the treatment of diabetes.
GGG Tri-Agonist Diabetes
Diabetes
- Diabetes
- Large Molecule
- NME
GGG Tri-Agonist Diabetes
Business area: Diabetes
"GGG Tri-Agonist" is a biologic entity being studied for the treatment of diabetes.
GLP-1 Receptor NPA
Diabetes
Milestone Achieved
- Diabetes
- Small Molecule
- NME
GLP-1 Receptor NPA
"GLP-1 Rec NPA" is a chemical entity being studied for the treatment of diabetes.
IDO1 Inhibitor
Cancer
- Oncology
- Small Molecule
- NME
IDO1 Inhibitor
"IDO1 Inhibitor" is a small molecule being studied for the treatment of cancer.
IL-2 Conjugate
Immunology
- Immunology
- Large Molecule
- NME
IL-2 Conjugate
"IL-2 Conjugate" is a large molecule being studied for the treatment of autoimmune diseases.
O-GlcNAcase Inhibitor Alzheimer's
Neurodegeneration
- Neurodegeneration
- Small Molecule
- NME
O-GlcNAcase Inhibitor Alzheimer's
Business area: Neuroscience
"O-GlcNAcase Inhibitor" is a chemical entity being studied for the treatment of Alzheimer's disease.
Oxyntomodulin
Diabetes
- Diabetes
- Large Molecule
- NME
Oxyntomodulin
"Oxyntomodulin" is a large molecule being studied for the treatment of diabetes.
PACAP38 Antibody
Pain
- Pain
- Large Molecule
- NME
PACAP38 Antibody
"PACAP38 Antibody" is a large molecule being studied for the treatment of pain.
PD-1 Antibody Agonist
Immunology
- Immunology
- Large Molecule
- NME
PD-1 Antibody Agonist
"PD-1 Antibody Agonist" is a large molecule being studied for the treatment of autoimmune diseases.
PD-1/PD-L1 Bispecific Antibody
Cancer
Milestone Achieved
- Oncology
- Large Molecule
- NME
PD-1/PD-L1 Bispecific Antibody
PD-1/PD-L1 Bispecific Antibody is a biologic entity being studied for the treatment of cancer.
SSTR4 Agonist
Pain
Milestone Achieved
- Pain
- Small Molecule
- NME
SSTR4 Agonist
"SSTR4 Agonist" is a chemical entity being studied for the treatment of Pain.
Tau Morphomer
Alzheimer's
Milestone Achieved
- Neurodegeneration
- Small Molecule
- NME
Tau Morphomer
"Tau Morphomer" is a chemical entity being studied for the treatment of Alzheimer's disease.
TIM-3 Monoclonal Antibody
Cancer
- Oncology
- Large Molecule
- NME
TIM-3 Monoclonal Antibody
"TIM-3 Monoclonal Antibody" is a large molecule being studied for the treatment of cancer.
TRPA1 Antagonist
Pain
Milestone Achieved
- Pain
- Small Molecule
- NME
TRPA1 Antagonist
"TRPA1 Antagonist" is a chemical entity being studied for the treatment of pain.
Aur A Kinase Inhibitor
Cancer
- Oncology
- Small Molecule
- NME
BAFF/IL-17 Bispecific Antibody
Immunology
- Immunology
- Large Molecule
- NME
Basal Insulin Acylated
Diabetes
- Diabetes
- Large Molecule
- NME
BTK Inhibitor
Cancer
- Oncology
- Small Molecule
- NME
BTLA Antibody Agonist
Immunology
- Immunology
- Large Molecule
- NME
cancer
Oncology
- Oncology
- NME
CD200R Antibody Agonist
Immunology
- Immunology
- Large Molecule
- NME
CXCR1/2 Ligands Monoclonal Antibody
Immunology
- Immunology
- Large Molecule
- NME
Dual Amylin Calcitonin Receptor Agonist
Diabetes
- Diabetes
- Large Molecule
- NME
ERK Inhibitor
Cancer
- Oncology
- Small Molecule
- NME
GDF15 Agonist
Diabetes
- Diabetes
- Large Molecule
- NME
GGG Tri-Agonist Diabetes
Diabetes
- Diabetes
- Large Molecule
- NME
GLP-1 Receptor NPA
Diabetes
- Diabetes
- Small Molecule
- Milestone Achieved
- NME
IDO1 Inhibitor
Cancer
- Oncology
- Small Molecule
- NME
IL-2 Conjugate
Immunology
- Immunology
- Large Molecule
- NME
O-GlcNAcase Inhibitor Alzheimer's
Neurodegeneration
- Neurodegeneration
- Small Molecule
- NME
Oxyntomodulin
Diabetes
- Diabetes
- Large Molecule
- NME
PACAP38 Antibody
Pain
- Pain
- Large Molecule
- NME
PD-1 Antibody Agonist
Immunology
- Immunology
- Large Molecule
- NME
PD-1/PD-L1 Bispecific Antibody
Cancer
- Oncology
- Large Molecule
- Milestone Achieved
- NME
SSTR4 Agonist
Pain
- Pain
- Small Molecule
- Milestone Achieved
- NME
Tau Morphomer
Alzheimer's
- Neurodegeneration
- Small Molecule
- Milestone Achieved
- NME
TIM-3 Monoclonal Antibody
Cancer
- Oncology
- Large Molecule
- NME
TRPA1 Antagonist
Pain
- Pain
- Small Molecule
- Milestone Achieved
- NME
Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently approved products that are in clinical development. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued or delayed, or to fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of July 29, 2019. Lilly assumes no duty to update this information.
For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being studied is listed.
Property of Eli Lilly and Company.
FREQUENTLY ASKED QUESTIONS
Thank you for visiting Lilly’s clinical development pipeline site. This interactive page is designed to give you a better understanding of the molecules and potential indications Lilly is currently developing for people around the world. Below are responses to some frequently asked questions regarding the site’s information and how it is displayed.